P3FI-63

CAS No. 931596-95-1

P3FI-63( —— )

Catalog No. M37503 CAS No. 931596-95-1

P3FI-63 is a selective KDM3B inhibitor (IC50: 7 μM) with antitumor activity for the study of fusion-positive rhabdomyosarcoma and other transcriptionally addictive cancers.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 29 In Stock
10MG 38 In Stock
25MG 69 In Stock
50MG 114 In Stock
100MG 184 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    P3FI-63
  • Note
    Research use only, not for human use.
  • Brief Description
    P3FI-63 is a selective KDM3B inhibitor (IC50: 7 μM) with antitumor activity for the study of fusion-positive rhabdomyosarcoma and other transcriptionally addictive cancers.
  • Description
    P3FI-63 is a selective KDM3B inhibitor (IC50: 7 μM) with antitumor activity for the study of fusion-positive rhabdomyosarcoma and other transcriptionally addictive cancers.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Histone Demethylase
  • Recptor
    Histone Demethylase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    931596-95-1
  • Formula Weight
    269.3
  • Molecular Formula
    C15H15N3O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NNC(=O)C=1C=C(C=C(C1)C)C)C2=NC=CC=C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • KDM5-IN-48

    A potent, selective and orally bioavailable KDM5 inhibitor with biochemical IC50 of 15.1, 4.7 and 65.5 nM for KDM5A, KDM5B and KDM5C, respectively.

  • Zavondemstat

    Zavondemstat (QC8222 free base) is a histone lysine demethylase 4 (KDM4) inhibitor with anticancer and antitumor activity for the study of triple-negative and breast cancers.

  • MRTX9768

    MRTX-9768 is a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors.